ARTICLE | Clinical News
HQK-1004: Phase II started
August 16, 2010 7:00 AM UTC
HemaQuest began an open-label, international Phase II trial to evaluate HQK-1004 plus IV ganciclovir for 5 days followed by oral valganciclovir for 16 days of each 3-week cycle for up to 6 cycles in u...